Lachesis BioSciences is a clinical-stage biotechnology company targeting dementia caused by Alzheimer’s and Parkinson’s disease.
Lachesis Biosciences is developing LBIO-R32, a rivastigmine nasal spray for the treatment of mild to severe Alzheimer's disease dementia and mild to moderate Parkinson’s disease dementia. Lachesis is pursuing a 505(b)(2) development pathway for LBIO-R32, which means the company can substantially rely on existing preclinical and clinical data generated by Novartis with rivastigmine for approval. From a development standpoint, this takes years and hundreds of millions off their plate. It's a significantly de-risked and expedited approach.
Company Details
- Employees
- 3
- Address
- 664 Collins St, Level 13,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- IT Consulting.
- HQ
- Docklands, Victoria
Lachesis Biosciences Questions
Lachesis Biosciences's website is https://www.lachesisbiosciences.com/
Lachesis Biosciences's LinkedIn profile is https://au.linkedin.com/company/lachesis-biosciences
Lachesis Biosciences has
3 employees.
View email and phone details for 3
employees at Lachesis Biosciences.
Lachesis Biosciences's industry is
Biotechnology Research
Lachesis Biosciences's top competitors are
Syngene International Limited,
Blinklab Limited (Asx:bb1),
Ezz Life Science Holdings Asx:ezz,
Global Pharma Solutions,
Cambium Bio,
Evithé Biotechnology,
Cad-It Australia Pty Ltd,
Jag Process Solutions Pty Ltd,
Purecdm,
Atticus Medical.
Lachesis Biosciences's categories are Biotechnology Research
